Brought to you by 
Celgene invests in Quanticel; holds purchase option; option exercised
20 Aug 2020
Executive Summary
Celgene Corp. has entered into an exclusive agreement with genomics start-up Quanticel Pharmaceuticals Inc. Celgene committed $45mm in funding during the initial three-and-a-half-year alliance term, took an undisclosed equity stake, and retains an exclusive option to both extend the deal and/or acquire the company.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene invests in Quanticel; holds purchase option; option exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice